glp 1 and ibd 🚨 GLP-1 RA use in is rising fast In this 14-month repeated survey of patients with IBD: 📈 GLP-1 RA use rose 5-fold ⚖️ Median BMI fell from 35.3 → 31.2 Frontiers | Inflammation Meets Metabolic

observed that in T2DM patients (mean age: 64.9 years) treated with subcutaneous semaglutide, reductions in the SMI were smaller than those in the fat mass index (FMI) [56], and the findings suggest a preservation of muscle strength and muscle quality

Qu for assay and technical support

The researchers noted that some of the studys findings were imprecise, and that continuous monitoring and further research will provide more precise risk estimates

Importantly, patients themselves are shaping this evolution

To substantially reduce confounding, we used inverse probability weighting, including a broad range of patient characteristics and proxies for diabetes severity

Health 8 (1), e001206